[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
We describe a postmenopausal woman suffering from advanced breast cancer with pleural effusion. She had prior anastrozole therapy, and was referred to our hospital with dyspnea. The use of exemestane, a highly selective steroidal aromatase inhibitor (25 mg daily), successfully induced remission of pleural effusion. Exemestane is a useful treatment for postmenopausal woman with advanced breast cancer, which is refractory to anastrozole.
Sakurai
Teruhisa
T
First Dept. of Surgery, Wakayama Medical University.
Oura
Shoji
S
Hirai
Issei
I
Tanino
Hirokazu
H
Yoshimas
Tatsuya
T
Kokawa
Yozo
Y
Nishida
Munehiro
M
Sasaki
Rie
R
Kinoshita
Takahiro
T
Bessho
Toshiya
T
Yokochi
Hiroya
H
Nishimura
Osamu
O
Okamura
Yoshitaka
Y
D000368:Aged; D000077384:Anastrozole; D000730:Androstadienes / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009570:Nitriles / Q000494:pharmacology*; D017698:Postmenopause; D014230:Triazoles / Q000494:pharmacology*
D000730:Androstadienes; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; C056516:exemestane